Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors: A National Danish Cohort Study
Patients with CD appear to have a lower risk of IMC than those with UC and MC. Despite an increased risk of IMC and severe IMC in patients with UC, CD, and MC, 72% of the patients were able to continue first-line treatment with ICI. Treatment with ICI in patients with UC, CD, and MC is overall well tolerated and should be considered on the basis of the same criteria as in patients without intestinal diseases.
Authors
- Jakob Benedict Seidelin (ORCID: https://orcid.org/0000-0003-3230-7966)
- Anders Kverneland (ORCID: https://orcid.org/0000-0002-9883-936X)
- Jacob Tveiten Bjerrum (ORCID: https://orcid.org/0000-0002-6249-3889)
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Katrine Risager Christensen (ORCID: https://orcid.org/0000-0002-3854-9467)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Henrik Jacobsen (ORCID: https://orcid.org/0000-0001-7939-0715)
- E. Dahl (ORCID: https://orcid.org/0000-0002-1383-5619)
- Anders Dige (ORCID: https://orcid.org/0000-0001-9995-0329)
Institutions
- University of Southern Denmark (DK)
- Aalborg University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1200/op-25-00390
- Primary Topic
- Microscopic Colitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00